申请人:Takeda Pharmaceutical Company Limited
公开号:EP1593673A1
公开(公告)日:2005-11-09
A compound represented by the formula:
wherein R1 is a 5- or 6-membered ring; R3 is a hydrogen atom, a lower alkyl group or a lower alkoxy group; R7 and R8 are each a hydrogen atom or a lower alkyl group; Z1 is another 5- or 6-membered aromatic ring; Z2 is a group represented by -Z2a-W1-Z2b- [wherein Z2a and Z2b are each O, S(O)m (wherein m is 0, 1 or 2), an imino group or a bond, and W1 is an alkylene chain]; X is CR (wherein R is a hydrogen atom, a lower alkyl group, a lower alkoxy group, an acyl group, or R and adjacent R4 may form a 5- or 6-membered alicyclic heterocyclic group) or N; R4 is NR5R6 (wherein R5 and R6 are each a hydrogen atom, a hydrocarbon group, a heterocyclic group or an acyl group), or R5 and R6 are bonded to each other to form a heterocyclic group of NR5R6; and R2 is (1) an amino group which may be a quaternary ammonium or oxide, (2) a nitrogen-containing heterocyclic group which may contain a sulfur atom or an oxygen atom as the ring-constituting atom, in which the nitrogen atom may be converted to a quaternary ammonium or an oxide, or the like; or a salt thereof.
The compound has excellent CCR5 antagonistic activity and thus is useful as a prophylactic and/or therapeutic medicine for HIV infection into human peripheral blood monocyte, especially for AIDS.
一种化合物,其化学式表示为:其中R1是一个5-或6-成员环;R3是氢原子、较低的烷基或较低的烷氧基;R7和R8分别是氢原子或较低的烷基;Z1是另一个5-或6-成员芳香环;Z2是一个由-Z2a-W1-Z2b-表示的基团[其中Z2a和Z2b分别是O、S(O)m(其中m为0、1或2)、亚胺基或键,W1是一个烷基链];X是CR(其中R是氢原子、较低的烷基、较低的烷氧基、酰基,或R和相邻的R4可能形成5-或6-成员脂环杂环基)或N;R4是NR5R6(其中R5和R6分别是氢原子、烃基、杂环基或酰基),或R5和R6相互连接形成NR5R6的杂环基;R2是(1)可能是季铵盐或氧化物的氨基团,(2)可能包含硫原子或氧原子作为构成环的原子的含氮杂环基,其中氮原子可以转化为季铵盐或氧化物,或类似物;或其盐。该化合物具有出色的CCR5拮抗活性,因此可用作预防和/或治疗HIV感染进入人类外周血单核细胞,特别是艾滋病的药物。